focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Share News (SAR)

Share Price Information for Sareum (SAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 34.00
Bid: 33.00
Ask: 35.00
Change: -3.25 (-8.72%)
Spread: 2.00 (6.061%)
Open: 37.50
High: 37.50
Low: 33.50
Prev. Close: 37.25
SAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS SUMMARY: M&S Gains, B&M Loses On Jefferies Ratings

Wed, 03rd Jun 2020 10:56

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Wednesday.

----------

FTSE 250 - WINNERS

----------

Chemring Group, up 24%. The defence technology company reported 37% revenue growth in the six months to the end of April to GBP191.0 million, taking pretax profit up to GBP19.0 million from GBP4.3 million a year ago. Chemring increased its interim payout by 8% to 1.3 pence a share. The company said its performance in the first half of its current financial year was ahead of expectations, reflecting strong performance in both segments of its business and some positive timing differences. Chemring reported good progress in securing new business in the UK, US and Australia for the supply of global countermeasures. Looking forward, Chemring said all of its businesses have remained open despite the challenges presented by Covid-19. Its full-year expectations are unchanged, despite the challenging environment, with about 95% of expected second-half revenue in the order book or delivered to date.

----------

Marks & Spencer Group, up 5.8%. Jefferies raised the UK retailer to Buy from Hold.

----------

FTSE 250 - LOSERS

----------

B&M European Value Retail, down 1.3%, Jefferies downgraded the UK retailer to Hold from Buy.

----------

OTHER MAIN MARKET AND AIM - WINNERS

----------

Cadence Minerals, up 42%. The company - which invests in lithium mining projects - said its joint venture partner Hastings Technology Metals entered into binding master agreement with the German automotive supplier Schaeffler Technologies for the targeted supply of its MREC, the product mined and processed from Yangibana project in the Gascoyne region, Western Australia. Hastings obligation is to supply a substantial volume of MREC over a period of 10 years as initial period. Cadence owns 30% of the Yangibana, Yangibana North, Gossan, Hook, Kanes Gossan and Lions Ear rare earth deposit, which form part of the Yangibana rare earth deposit. "This contract represents a very important milestone in the development of Hastings as an emerging supplier of rare earth carbonate from Australia to Germany, an industrialised nation with a growing demand for a critical raw material used in many advanced technologies where a permanent magnet is needed," said Hastings Chair Charles Lew.

----------

Bluerock Diamonds, up 22%. The diamond producer reported no cases of Covid-19 at the Kareevlei diamond mine in the Kimberley region of South Africa. Bluerock said production averaged almost 2,000 tons a day since May 11 to bring total to 41,500 tons, which is 65% higher than the average daily production in the prior record quarter to the end of 2019. "The modifications made to the primary crushing circuit and the introduction of the third pan together with the processing of softer near surface material have allowed us to increase production at minimal cost whilst also reducing operating costs," said Executive Chair Mike Houston.

----------

React Group, up 12% at 1.70 pence. The carpet cleaning company said it placed 83.1 million shares at a price of 1.5p each, raising GBP1.3 million before expenses. The placing was materially oversubscribed following demand from both new and existing institutional and other investors. React said it intends to use the proceeds from the fundraising to strengthen its sales and marketing activities, and support a growing contract pipeline and accelerate organic growth. In addition, the proceeds will go towards additional working capital and to strengthen the company's balance sheet to support its aspiration to secure larger contracts. "This oversubscribed fundraise recognises the progress achieved so far and provides React with the working capital and balance sheet strength to support ambitions for further sustainable and profitable growth," said Chief Executive Shaun Doak.

----------

OTHER MAIN MARKET AND AIM - LOSERS

----------

Sareum Holdings, down 16% at 0.59p. The pharmaceutical company said it has completed a fundraising, comprising a placing by Hybridan in conjunction with an offer via PrimaryBid. Sareum said it raised GBP303,722 through a shares issue at a price of 0.6p per share. Accordingly, combined with the placing, the company has raised a total of GBP1.0 million. "We believe that our TYK2/JAK1 inhibitor candidates - SDC-1801 and SDC-1802 - represent exciting prospects. The way they act continues to be a focus for the broader industry interested in treating autoimmune diseases, cancer and more recently in addressing the severe respiratory symptoms associated with advanced Covid-19. These new funds will be used to advance their preclinical studies targeting completion in at least one indication late this year, pending successful progress," said Chief Executive Tim Mitchell.

----------

Beowulf Mining, down 9.2%. The exploration and development company said Chief Executive Kurt Budge has written to Ibrahim Baylan, minister for Business, Industry and Innovation, the government of Sweden. "Beowulf has several thousand Swedish shareholders, who own over 67 per cent of the company. They have witnessed the government's unacceptable mishandling of the Kallak application and false promises; the opportunity cost of which is incalculable. They are demanding the government be fully transparent now and remove all uncertainty as to when a decision on Kallak will be taken," Budge wrote. Beowulf said it is ready to play its part in Sweden's economic recovery, to advance Kallak in partnership with the community in Jokkmokk.

----------

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
13 Jun 2019 15:49

Sareum Plans To Start Human Trials Of Two Drug Candidates In 2020

(Alliance News) - Sareum Holdings PLC on Thursday said it has been focusing on toxicology studies in its development of drug candidates SDC-1801 and SDC-1802 with a view to CONDUCT human trials in

Read more
3 Jun 2019 17:38

Sareum Notes Sierra Oncology's Positive Preliminary Results Of SRA737

LONDON (Alliance News) - Sareum Holdings PLC on Monday said it noted its licensee Sierra Oncology's webcast discussing clinical findings and possible next steps for SRA737, its oral checkpoint

Read more
3 Jun 2019 10:02

Sareum Reports Positive Data From Trials Of SRA737 In Advanced Cancer

LONDON (Alliance News) - Sareum Holdings PLC on Monday said that Sierra Oncology reported positive preliminary clinical data from two in-human studies of SRA737.Shares in the drug company a

Read more
4 Mar 2019 10:58

Sareum Interim Loss Deepens On Costs As Pipeline Continues Progress

LONDON (Alliance News) - Cancer drug discovery firm Sareum Holdings PLC said Monday its interim loss widened as costs rose, but it made progress with its key developmental programmes.For to

Read more
4 Mar 2019 08:26

Sareum's loss widens as development costs expand

(Sharecast News) - Sareum Holdings' shares dropped on Monday after the company reported a widened interim loss due to rising costs, though it stated progress had been made with key development programmes.

Read more
28 Feb 2019 14:33

Sareum flags potentially significant findings for SRA737

(Sharecast News) - Specialist small molecule drug development company Sareum Holdings announced on Thursday that Sierra Oncology, the licence holder advancing clinical cancer candidate SRA737, had reported that an abstract reporting preclinical data for SRA737 - its Chk1 inhibitor - plus low dose gemcitabine (LDG), in combination with immunotherapy, had been selected for a late-breaking oral presentation at the American Association of Cancer Research annual meeting.

Read more
11 Dec 2018 15:55

UK Shareholder Meetings Calendar - Next 7 Days

Wednesday 12 DecemberBlancco Technology GroupBellwayVolution Shopping REIT (re voluntary 13 Asian 14 to

Read more
30 Nov 2018 11:48

Sareum Reports Efficacy Data For Immunotherapy Combination With SRA737

LONDON (Alliance News) - Sareum Holdings PLC said Friday that Sierra Oncology Inc reported preclinical efficacy data for an immunotherapy combination with its SRA737 inhibitor in lung licences the

Read more
26 Oct 2018 09:20

Sareum Holdings Raises GBP850,000 Via Share Placing (ALLISS)

LONDON (Alliance News) - Sareum Holdings PLC said Friday it raised GBP850,000 via the issue of 130.8 million shares to fund the development of its lead cancer and autoimmune drugs.The drug

Read more
26 Oct 2018 08:38

Sareum raises £850,000 to fund cancer inhibitor

(Sharecast News) - Drug maker Sareum has raised £850,000 to progress the development programme of its cancer inhibitor TYK2/JAK1.

Read more
1 Oct 2018 11:30

Sareum Swings To Annual Loss After Prior Year Profit From Associates

LONDON (Alliance News) - Sareum Holdings PLC on Monday said it swung to an annual loss after reporting a substantial share of profit from associates the year before.Shares in Sareum were at

Read more
26 Sep 2018 15:20

Sareum Holdings selects cancer therapy development candidate

(Sharecast News) - Drug discovery and development company Sareum Holdings has made the formal selection of a development candidate from its TYK2 inhibitor programme to advance through preclinical development as a potential new targeted therapy for certain cancers, it announced on Wednesday.

Read more
26 Sep 2018 14:05

Sareum Selects Candidate To Develop Cancer Treatment

LONDON (Alliance News) - Sareum Holdings PLC said Wednesday that it has selected the SDC-1802 molecule from the TYK2 inhibitor programme for further development as potential treatment for certain

Read more
11 Sep 2018 13:28

Sareum Holdings Expects To Swing To GBP1.5 Million Annual Loss

LONDON (Alliance News) - Sareum Holdings PLC said Tuesday it expects to report a loss in its annual results as it progresses on its programmes in autoimmune diseases and cancer.The drug it

Read more
10 Sep 2018 11:52

Sareum Picks SDC-1801 For Development As Autoimmune Disease Treatment

LONDON (Alliance News) - Sareum Holdings PLC said Monday it will develop SDC-1801 as a possible treatment for autoimmune diseases.The molecule, SDC-1801, has been formally selected for is a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.